CRVS
Price
$3.90
Change
+$0.15 (+4.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
301.13M
68 days until earnings call
SYRE
Price
$16.61
Change
+$0.09 (+0.54%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1B
56 days until earnings call
Interact to see
Advertisement

CRVS vs SYRE

Header iconCRVS vs SYRE Comparison
Open Charts CRVS vs SYREBanner chart's image
Corvus Pharmaceuticals
Price$3.90
Change+$0.15 (+4.00%)
Volume$7.95K
Capitalization301.13M
Spyre Therapeutics
Price$16.61
Change+$0.09 (+0.54%)
Volume$6.97K
Capitalization1B
CRVS vs SYRE Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. SYRE commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Buy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CRVS: $3.90 vs. SYRE: $16.61)
Brand notoriety: CRVS and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 41% vs. SYRE: 56%
Market capitalization -- CRVS: $301.13M vs. SYRE: $1B
CRVS [@Biotechnology] is valued at $301.13M. SYRE’s [@Biotechnology] market capitalization is $1B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, CRVS is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • CRVS’s TA Score: 6 bullish, 4 bearish.
  • SYRE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than SYRE.

Price Growth

CRVS (@Biotechnology) experienced а +2.76% price change this week, while SYRE (@Biotechnology) price change was +6.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1B) has a higher market cap than CRVS($301M). SYRE (-29.038) and CRVS (-29.907) have similar YTD gains . CRVS has higher annual earnings (EBITDA): -31.13M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. CRVS (44.2M). SYRE has less debt than CRVS: SYRE (0) vs CRVS (1.15M). CRVS (0) and SYRE (0) have equivalent revenues.
CRVSSYRECRVS / SYRE
Capitalization301M1B30%
EBITDA-31.13M-214.36M15%
Gain YTD-29.907-29.038103%
P/E RatioN/A1.72-
Revenue00-
Total Cash44.2M565M8%
Total Debt1.15M0-
FUNDAMENTALS RATINGS
CRVS vs SYRE: Fundamental Ratings
CRVS
SYRE
OUTLOOK RATING
1..100
2211
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
4764
P/E GROWTH RATING
1..100
9881
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRVS's Valuation (65) in the Pharmaceuticals Major industry is in the same range as SYRE (75). This means that CRVS’s stock grew similarly to SYRE’s over the last 12 months.

CRVS's Profit vs Risk Rating (91) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that CRVS’s stock grew similarly to SYRE’s over the last 12 months.

CRVS's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as SYRE (95). This means that CRVS’s stock grew similarly to SYRE’s over the last 12 months.

CRVS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as SYRE (64). This means that CRVS’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as CRVS (98). This means that SYRE’s stock grew similarly to CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEDAX11.44N/A
N/A
Voya Large Cap Value A
IRVAX24.13N/A
N/A
Voya Russell Large Cap Value Idx Port A
ECASX27.29N/A
N/A
Eaton Vance Atlanta Capital SMID-Cap C
APPIX15.38N/A
N/A
Appleseed Institutional
MGLMX16.43N/A
N/A
MFS Global Real Estate R4

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-8.98%
SYRE - CRVS
37%
Loosely correlated
-0.30%
VKTX - CRVS
35%
Loosely correlated
+1.47%
IPSC - CRVS
34%
Loosely correlated
-0.54%
FULC - CRVS
34%
Loosely correlated
-0.07%
VCYT - CRVS
33%
Poorly correlated
+2.98%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-0.30%
BEAM - SYRE
58%
Loosely correlated
+1.60%
CGON - SYRE
57%
Loosely correlated
-0.78%
IMNM - SYRE
53%
Loosely correlated
-2.59%
APGE - SYRE
53%
Loosely correlated
-1.56%
XNCR - SYRE
53%
Loosely correlated
-0.44%
More